Press ReleaseIronwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy Press Release / lsc-webmaster
Press ReleaseU.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC) Press Release / lsc-webmaster
Press ReleaseFDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals Press Release / lsc-webmaster
Press ReleaseTakeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study Press Release / lsc-webmaster
Press ReleaseCour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA Press Release / lsc-webmaster
Press ReleaseCour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease Press Release / lsc-webmaster
Press ReleaseTakeda and Cour Partner to Develop Novel Therapies for Celiac Disease Press Release / lsc-webmaster
Press ReleaseCour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease Press Release / lsc-webmaster
